Although endocrine therapy is the most common systemic treatment for ERα-positive breast cancer in clinical practice, approximately 40% of patients still develop primary or secondary resistance to endocrine therapy (Badia et al., 2007; Légaré and Basik, 2016; Rondón-Lagos et al., 2016). Here, ESR1 is linked to breast cancer.